NASDAQ · Biotechnology

ORIC (ORIC) Stock

$13.50 +4.41% NASDAQ: ORIC Healthcare

Valuation

MetricValue
Price$13.50
Market Cap$1.40B
P/E Ratio-5.39
P/B Ratio2.11
P/S Ratio0.00
EPS (TTM)$-1.54
52-Week High$14.93
52-Week Low$7.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.57%
ROA-27.57%
ROCE-37.24%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.40

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-79.0M$-92.0M$-111.0M$-143.0M$-143.0M
Net Profit$-79.0M$-89.0M$-101.0M$-128.0M$-129.0M
EPS$-2.07$-2.25$-1.96$-1.83$-1.47
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$299.0M$250.0M$255.0M$274.0M$411.0M
Total Liabilities$26.0M$28.0M$31.0M$31.0M$27.0M
Cash$226.0M$67.0M$23.0M$59.0M$46.0M
Borrowings$2.0M$12.0M$10.0M$3.0M$12.0M

Latest News

ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer MT Newswires · Jul 14, 2026 ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer GlobeNewswire · Jul 14, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire · May 27, 2026 Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth Simply Wall St. · May 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-60.0M$-75.0M$-86.0M$-113.0M$-113.0M
Investing Cash Flow$157.0M$-111.0M$-44.0M$21.0M$-149.0M
Financing Cash Flow$-1.0M$0$1.0M$2.0M$0
Net Cash Flow$148.0M$-159.0M$-43.0M$36.0M$-14.0M
Free Cash Flow$-60.0M$-77.0M$-87.0M$-114.0M$-114.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-3.93
FCF Yield-12.67%
Quick Ratio16.33
Interest Coverage—
Return 1Y-7.71%
Return 3Y23.47%
Return 5Y-45.48%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About ORIC

ORIC is led by CEO Jacob Chacko, employs 122 people, headquartered in US, publicly traded since 2020.

ORIC stock trades at $13.50 with a market capitalization of $1.40B. The stock is valued at a price-to-earnings (P/E) ratio of -5.39, price-to-book of 2.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.23 and $14.93, and currently trades 9.6% below its 52-week high.

On profitability, ORIC generates a return on equity (ROE) of -42.57%, return on capital employed of -37.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides